Betta Pharmaceuticals Co., Ltd. (SZ300558), established in 2003 in Hangzhou, China, is one of the leading Chinese pharmaceutical companies dedicated to develop and commercialize innovative oncology products to meet high unmet medical needs. With over 1,300 employees in Hangzhou and Beijing, China, Betta’s development capabilities range from small molecule and biologics discovery, clinical development, registration, manufacturing, sales and marketing. Betta’s leading product – icotinib (Conmana®), the first innovative oncology product developed and commercially launched by a Chinese pharmaceutical company – is the No.1-selling targeted therapy treating non-small cell lung cancer patients carrying EGFR mutations in China, having achieved 1.25 billion RMB annual sales in 2018. Betta currently has three programs under late-stage clinical development, three programs under proof-of-concept clinical development, two programs under IND review by the NMPA and close to twenty programs under pre-clinical development. Betta has set up joint ventures with Amgen Inc. (AMGN) and Tyrogenex Inc. and is the majority shareholder of Xcovery LLC. For additional information, please visit http://en.bettapharma.com.